Fertility choices and management for HIV-positive women

Current Opinion in HIV and AIDS

Volumn 3, Issue 2, 2008, Pages 186-192

  Coll, Oriol ^a,b,c   Lopez, Marta ^a   Hernandez, Sandra ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Clinica EUGIN   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Assisted reproduction; Contraception; Fertility; HIV; Pregnancy

Indexed keywords

ANTIRETROVIRUS AGENT; MICROBICIDE; RIFAMPICIN;

CONDOM; CONTRACEPTION; FAMILY PLANNING; FEMALE FERTILITY; FEMALE STERILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ILLEGAL ABORTION; INTRAUTERINE CONTRACEPTIVE DEVICE; LEGAL ABORTION; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; REPRODUCTIVE HEALTH; REVIEW; RISK ASSESSMENT; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE;

EID: 40049100193     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282f51219     Document Type: Review

References (89)

1. Center for Reproductive Rights. Reproductive rights 2000: moving forward. New York: Center for Reproductive Rights; 2003.
2. Lusti-Narasimhan M, Cottingham J, Berer M. Ensuring the sexual and reproductive health of people living with HIV: policies, programmes and health services. Reprod Health Matters 2007; 15 (29 (Suppl)):1-3. This review is an interesting document, as it underlines the need to adapt policies and programmes to all infected patients' adequate reproductive healthcare.
3. World Health Organization. Sexual and reproductive health of women living with HIV/AIDS. Guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings. Geneva: WHO and UNFPA; 2006. This document offers the official guidelines by the WHO on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings.
4. World Health Organization. Joint WHO/UNAIDS/UNFPA Policy Statement. Dual protection against unwanted pregnancy and sexually transmitted infections, including HIV. Geneva: WHO; 2000.
5. th revised ed. New York: Ardent Media; 2004.
6. Hatzell Hoke T, Deperthes B. Effectiveness of female condom in the prevention of pregnancy and sexually transmitted diseases. PATH Global Consultation on the Female Condom. Baltimore, 26-29 September 2005. www.path.org/projects/womans_condom_gcfc2005.php. [Accessed 13 December 2007]
7. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002; (1):CD003255.
8. Drew WL, Blair M, Miner RC, et al. Evaluation of the virus permeability of a new condom for women. Sex Transm Dis 1990; 17:110-112.
9. French PP, Latka M, Gollub EL, et al. Use-effectiveness of the female versus male condom in preventing sexually transmitted disease in women. Sex Transm Dis 2003; 30:433-439.
10. Moench TR, Chipato T, Padian NS. Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices. AIDS 2001; 15:1595-1602.
11. Minnis AM, Padian NS. Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions. Sex Transm Infect 2005; 81:193-200.
12. Berer M. Dual protection: making sex safer for women. Reprod Health Matters 1997; 14:109-121.
13. Degu G, Yimer G, Berhane Y, et al. Reproductive health needs of PLWHA on ART. Linking reproductive health, family planning, and HIV/AIDS in Africa. Conference Proceedings. Addis Ababa, 9-10 October 2006. http://www. jhsph.edu/gatesinstitute/_pdf/policy_practice/FP-HIV/Presentations/Session %205B/Melkamu_%20addis_ppt.pdf. [Accessed 18 December 2007]
14. Rutenberg N, Baek C. Review of field experiences: integration of family planning and PMTCT services. New York: Population Council, 2004.
15. Ministry of Health, Rwanda. Evaluation of access to and utilization of prevention of mother-to-child transmission (PMTCT) services in Rwanda. Kigali: TRAC, ICAP, EGPAF; 2007.
16. Cooper D, Myer L, Zweigenthal V, et al. Addressing reproductive intentions and reproductive healthcare needs among HIV positive women and men in Cape Town, South Africa. Linking Reproductive Health, Family Planning, and HIV/AIDS in Africa. Conference Proceedings. Addis Ababa, 9-10 October 2006. http://www.jhsph.edu/gatesinstitute/_pdf/policy_practice/FP-HIV/Presentations/ Session%202B/Cooper_addis.pdf. [Accessed 18 December 2007].
17. Adamchak S, Janowitz B, Amenyah R, et al. Family planning use and unmet need among female ART Clients in Ghana. Linking Reproductive Health, Family Planning, and HIV/AIDS in Africa. Conference Proceedings. Addis Ababa, 9-10 October 2006. http://www.jhsph.edu/gatesinstitute/_pdf/policy_practice/FP- HIV/Presentations/Session%202B/Adamchak_et%20al%20v4%20c. pdf. [Accessed 18 December 2007].
18. Sarna A, Luchters S, Shikely K, et al. Fertility intentions and family planning experiences among ART clients in Mombasa, Kenya. Linking Reproductive Health, Family Planning, and HIV/AIDS in Africa. Conference Proceedings. Addis Ababa, 9-10 October 2006. http://www.jhsph.edu/ gatesinstitute/_pdf/policy_practice/FP-HIV/Presentations/Session%205B/ Rutenberg_ART_Kenya.pdf. [Accessed 18 December 2007].
19. Balzarini J, Van Damme L. Intravaginal and intrarectal microbicides to prevent HIV infection. CMAJ 2005; 172:461-464.
20. rd ed. Geneva: World Health Organization; 2004.
21. Stringer EM, Kaseba C, Levy J, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 2007; 197:144.e1-144.e8. This study provides the most recent evidence that the IUD is effective and safe in HIV-infected women but results suggested that hormonal contraception was associated with more rapid HIV disease progression.
22. Baeten JM, Lavreys L, Overbaugh J. The influence of hormonal contraceptive use on HIV-1 transmission and disease progression. Clin Infect Dis 2007; 45:360-369. This paper reviews biological and epidemiological studies that suggest that hormonal contraceptive use could influence susceptibility to HIV-1, as well as infectivity and disease progression for those who become infected.
23. Mostad SB, Overbaugh J, DeVange DM, et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 1997; 350:922-927.
24. Richardson BA, Otieno PA, Mbori-Ngacha D, et al. Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women. AIDS 2007; 21:749-753. This study suggested that hormonal contraception had no immediate or longer-term effects on the rate of disease progression in chronically HIV-1-infected postpartum women.
25. Morrison CS, Richardson BA, Miro F, et al. Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21:85-95. The results provide encouragement that hormonal contraceptives may not affect a women's risk of HIV acquisition.
26. Morrison CS. Commentary. Hormonal contraception and HIV acquisition: current evidence and ongoing research needs. Int J Epidemiol 2007; 36: 175-177. This paper extensively reviews the available evidence of hormonal contraception and HIV acquisition.
27. Myer L, Denny L, Wright TC, Kuhn L. Prospective study of hormonal contraception and women's risk of HIV infection in South Africa. Int J Epidemiol 2007; 36:166-174. This study further suggested that hormonal contraception is not associated with an increased risk of HIV acquisition.
28. Raymond EG, Moench T, Feldblum P, Hubacher D. Response to Morrison et al., 'Hormonal contraception and the risk of HIV acquisition'. AIDS 2007; 23: 21-28. This correspondence suggest that the results by Morrison et al. (2007) require a randomized study before making any final conclusion.
29. Teal S, Ginosar D. Contraception for women with chronic medical conditions. Obstet Gynecol Clin North Am 2007; 34:113-126. This recent paper reviews current knowledge on contraception for women with several chronic medical conditions including HIV.
30. Grimes DA, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. Cochrane Database Syst Rev 2001; (2):CD001327.
31. Grimes DA, Schulz KF. Prophylactic antibiotics for intrauterine device insertion: a metaanalysis of the randomized controlled trials. Contraception 1999; 60:57-63.
32. Richardson BA, Morrison CS, Sekadde-Kigondu C, et al. Effect of cervical shedding of HIV-1 DNA. AIDS 1999; 13:2091-2097.
33. World Health Organization. Unsafe abortion: Global and regional estimates of incidence and associated mortality in 2000. 4th ed. Geneva: WHO; 2004.
34. Delvaux T, Nöestlinger C. Reproductive choice for women and men living with HIV: contraception, abortion and fertility. Reprod Health Matters 2007; 15 (29 Suppl):46-66. This paper reviews the literature on the fertility-related needs of women and men living with HIV access to contraception, abortion and fertility services are specifically discussed.
35. UNAIDS. Where prevention and care meet: voluntary counseling and testing, and preventing mother-to-child transmission. In: Report on the Global HIV/ AIDS Epidemic 2002. Geneva: UNAIDS; 2002. pp. 122-132.
36. Feldman R, Manchester J, Maposhere C. Positive women: voices and choices. Zimbabwe Report. Harare: SAfAIDS; 2002.
37. Koetsawang S, Auamkul N. HIV and women in Thailand: severity and services. Int J Gynaecol Obstet 1997; 58:121-127.
38. Kuyoh M, Best K. HIV-positive women have different needs. Network 2001; 20(4). http://www.fhi.org/en/rh/pubs/network/v20_4/nwvol20-4hivposwomen.htm [Accessed 13 December 2007].
39. de Bruyn M. HIV/AIDS and reproductive health. Sensitive and neglected issues. A review of the literature. Recommendations for action. Chapel Hill: Ipas; 2005.
40. de Bruyn M. Safe Abortion for HIV-positive women with unwanted pregnancy: a reproductive right. Reprod Health Matters 2003; 11:152-161.
41. Bongain A, Berrebi A, Marine-Barjoan E, et al. Changing trends in pregnancy outcome among HIV-infected women between 1985 and 1997 in two southern French university hospitals. Eur J Obstet Gynecol Reprod Biol 2002; 104:124-128.
42. van Benthem BH, de Vincezi I, Delmas MC, et al. Pregnancies before and after HIV diagnosis in a European cohort of HIV-infected women. European Study on the Natural History of HIV Infection in Women. AIDS 2000; 14:2171-2178.
43. Desgrees-Du-Lou A, Msellati P, Viho I, et al. Ditrame Study Group. Contraceptive use, protected sexual intercourse and incidence of pregnancies among African HIV-infected women. DITRAME ANRS 049 Project, Abidjan 1995-2000. Int J STD AIDS 2002; 13:462-468.
44. Lichtenberg PM, Borgatta L, et al. A clinician's guide to medical and surgical abortion. Philadelphia: Churchill Livingstone; 1999.
45. World Health Organization. Safe abortion: technical and policy guidance for health systems. Geneva: WHO; 2003.
46. Rabkin M, El-Sadr W, Abrams E. The Columbia Clinical Manual. New York: Mailman School of Public Health, Columbia University; 2004.
47. Women at Barcelona, Mujeres Adelante, International Women's AIDS Causus, International AIDS Society, International Community of Women Living with HIV/AIDS. Barcelona Bill of Rights. Geneva: IAS; 2002.
48. Newell ML, Huang S, Fiore S, et al. Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA. BMC Infect Dis 2007; 7:60-69.
49. Myer L, Morroni C and Rebe K. Prevalence and determinants of fertility intentions of HIV-infected women and men receiving antiretroviral therapy in South Africa. AIDS Patient Care STDs; 21:278-285.
50. Stanwood NL, Cohn SE, Heiser JR, Pugliese M. Contraception and fertility plans in a cohort of HIV-positive women in care. Contraception 2007; 75: 294-298.
51. Watts H, Li D, Handelsman E, et al. Assessment of birth defects according to maternal therapy among infants in the women and infants transmission study. J Acquir Immune Defic Syndr 2007; 44:299-305. A multicenter prospective observational study based on the WITS cohort in the US showed interesting prospective data with new information on the risk of antiretroviral pregnancy and birth defects.
52. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry international interim report for 1 January 1989 through 1 January 2007. Washington, DC : Antiretroviral Pregnancy Registry Steering Committee; 2007. Results of this prospective cohort offer the best estimate on the risk of antiretrovirals globally and individually during pregnancy.
53. US Department of Health and Human Services, Public Health Service. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Supplement: safety and toxicity of individual antiretroviral agents in pregnancy. Washington, DC: US Department of Health and Human Services, Public Health Service; 2006. This document extensively reviews all current knowledge on the risk associated to the use of antiretroviral treatment during pregnancy, not only on congenital anomalies, but also on toxic effects.
54. Mofenson LM. Efavirenz reclassified as FDA pregnancy category D. AIDS Clin Care 2005; 17:17.
55. Jeantils V, Khuong MA, Delassus JL, et al. Efavirenz (Sustiva) in pregnancy: a study about 12 HIV patients. Gynecol Obstet Fertil 2006; 34:593-596.
56. Patel D, Thorne C, Fiore S, et al. Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women? J Acquir Immune Defic Syndr 2005; 40:116-118.
57. Towsend C, Tookey P, Cortina-Borja M, et al. Antiretroviral therapy and congenital abnormalities in infants born to HIV-1-infected women in the United Kingdom and Ireland, 1990 to 2003. J Acquir Immune Defic Syndr 2006; 42:91-94. Results from analysis of 3120 pregnancies about congenital abnormalities among HIV-infected pregnant women, depending on type and moment of use of antiretroviral therapy, adjusted for confounding factors.
58. Thorne C, Newell ML. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern? Drug Saf 2007; 30:203-213.
59. Coll O, Lopez M, Vidal R, et al. Fertility assessment in noninfertile HIV-infected women and their partners. Reprod Biomed Online 2007; 14:488-494. Results of this cohort of HIV-infected women seeking pregnancy suggest that tubal factors are very prevalent among HIV infected women.
60. Ethical Issues in Obstetrics and Gynecology. FIGO Committee for the Ethical Aspects of Human Reproduction and Women's Health. November 2006. http://www.figo.org/docs/Ethics%20Guidelines.pdf [Accessed 18 December 2007].
61. Ethics Committee of the American Society for Reproductive Medicine. Human immunodeficiency virus and infertility treatment. Fertil Steril 2004; 82:S228-S231.
62. Frodsham L, Boag F, Barton S, Gilling-Smith C. Human immunodeficiency virus infection and fertility care in United Kingdom: demand and supply. Fertil Steril 2006; 85:285-289.
63. van Leeuwen E, Prins JM, Jurriaans S, et al. Reproduction and fertility in human immunodeficiency virus type-1 infection. Hum Reprod Update 2007; 13: 197-206. This paper is an updated review of the literature concerning HIV and reproduction and fertility for both infected men and women.
64. Bujan L, Hollander L, Coudert M, et al. Safety and efficacy of sperm washing in HIV-1 serodiscordant couples where the male is infected: results from the European CREAThe network. AIDS 2007; 21:1909-1914. This study of a European cohort of assisted reproduction when the man is infected with HIV provided the most information on the results of programs offering 'sperm wash' to avoid sexual transmission.
65. Barreiro P, Romero J, Leal M, et al. Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43:324-326. A retrospective study with a new point of view about reproductive options among HIV-infected men on the HAART era should be evaluated with caution but nevertheless is of interest.
66. Semprini AE, Levi-Setti P, Bozzo M, et al. Insemination of HIV-negative women with processed semen of HIV-positive partners. Lancet 1992; 340:1317-1319.
67. Pasquier C, Andreson D, Andreutti-Zaugg C, et al. Multicenter quality control of the detection of HIV-1 genome in semen before medically assisted procreation. J Med Virol 2006; 78:877-882. This study evaluated the performance of the technical protocols used to detect and quantify HIV-1 in 11 centers providing medically assisted procreation for couples with HIV-1 infected men by testing panels of seminal plasma and cells containing HIV-1 RNA or DNA.
68. Sauer MV. Sperm washing techniques address the fertility needs of HIVseropositivemen: a clinical review. Reprod Biomed Online 2005; 10:135-140.
69. Savasi V, Ferrazzi E, Lanzani C, et al. Safety of sperm washing and ART outcome in 741 HIV-1-serodiscordant couples. Hum Reprod 2007; 22:772-777.
70. Bujan L, Sergerie M, Moinard N, et al. Decreased semen volume and spermatozoa motility in HIV-1-infected patients under antiretroviral treatment. J Androl 2007; 28:444-452.
71. Bujan L, Daudin M, Moinard N, et al. Azoospermic HIV-1 infected patients wishing to have children: proposed strategy to reduce HIV-1 transmission risk during sperm retrieval and intracytoplasmic sperm injection: Case Report. Hum Reprod 2007; 22:2377-2381. This study discussed what could be done when an HIV-infected man is azoospermic and conventional detection of HIV in the spermatozoa fraction is difficult.
72. Nicopoullos J, Frodsham L, Ramsay J, et al. Synchronous sperm retrieval and sperm washing in an intracytoplasmic sperm injection cycle in an azoospermic man who was positive for human immunodeficiency virus. Fertil Steril 2004; 81:670-674.
73. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1 infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133:447-454.
74. Zaba B, Gregson S. Measuring the impact of HIV on fertility in Africa. AIDS 1998; 12 (Suppl 1):S41-S50.
75. Lo JC, Schambelan M. Reproductive function in human immunodeficiency virus infection. J Clin Endocrinol Metab 2001; 86:2338-2343.
76. Sedgh G, Larsen U, Spiegelman D, et al. HIV-1 disease progression and fertility in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr 2005; 39:439-445.
77. Nguyen RH, Gange SJ, Wabwire-Mangen F, et al. Reduced fertility among HIV-infected women associated with viral load in Rakai district, Uganda. Int J STD AIDS 2006; 17:842-846. This study suggested that there may be considerable differences in the ability to produce a live birth among HIV-positive women with high viral loads.
78. Clark RA, Mulligan K, Stamenovic E, et al. Frequency of anovulation and early menopause among women enrolled in selected adult AIDS clinical trials group studies. J Infect Dis 2001; 184:1325-1327.
79. Englert Y, Lesage B, Van Vooren JP, et al. Medically assisted reproduction in the presence of chronic viral diseases. Hum Reprod Update 2004; 10:149-162.
80. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18:1615-1627.
81. Frankel RE, Selwyn PA, Mezger J, Andrews S. High prevalence of gynecologic disease among hospitalized women with human immunodeficiency virus infection. Clin Infect Dis 1997; 25:706-712.
82. Sobel JD. Gynecologic infections in human immunodeficiency virus infected women. Clin Infect Dis 2000; 31:1225-1233.
83. van der Kuyl AC, Kozaczynska K, van den Burg R, et al. Triple HIV-1 infection. N Engl J Med 2005; 352:2557-2559.
84. Terriou P, Auquier P, Chabert-Orsini V, et al. Outcome of ICSI in HIV-1-infected women. Hum Reprod 2005; 20:2838-2843.
85. Coll O, Suy A, Figueras F, et al. Decreased pregnancy rate after in-vitro fertilization in HIV-infected women receiving HAART. AIDS 2006; 20:121-123. This case-control study on IVF among HIV-infected women clearly suggested that infected women have a lower risk to become pregnant, that this situation may be due to ovarian resistance and that it may be corrected by oocyte donation.
86. Martinet V, Manigart Y, Rozenberg S, et al. Ovarian response to stimulation of HIV-positive patients during IVF treatment: a matched, controlled study. Hum Reprod 2006; 21:1212-1217.
87. Jamieson DJ, Clark J, Kourtis A, et al. Recommendations for human immunodeficiency virus screening, prophylaxis, and treatment for pregnant women in the United States. Am J Obstet Gynecol 2007; 197 (3 Suppl):S26-S32. This paper reviews the recommendations regarding HIV during pregnancy related to screening, prophylaxis and treatment for pregnant women including who to treat and to perform an elective caesarean section.
88. Nesheim S, Jamieson DJ, Danner SP. Primary human immunodeficiency virus infection during pregnancy detected by repeat testing. Am J Obstet Gynecol 2007; 197:149.e1-149.e5. This study suggested that repeat HIV testing in pregnancy can identify opportunities for antiretroviral prophylaxis and should be used in areas of high HIV prevalence.
89. Manning SE, Pfeiffer MR, Nash D, et al. Incident sexually transmitted infections among persons living with diagnosed HIV/AIDS in New York City, 2001-2002: a population-based assessment. Sex Transm Dis 2007; 29 Jun [Epub ahead of print].